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Claudius Regaud will mostly be remembered as the father 
of fractionation and therefore the possibility to spare 
better normal tissues than tumors. Already in 1906, he 
hypothesized that X-rays could be used against rapidly 
growing cells other than gametes, such as cancer. 
Historical experiments in rams indeed established the 
concept of fractionation. Regaud was a pathologist who 
tried to understand the biology of radiation in a real 
multidisciplinary way.  
  While even in the earlier days of radiotherapy attempts 
were made to test hypotheses in pre-clinical models and 
to understand the underlying biology, increasingly 
hypotheses were directly applied in patients. Large 
numbers of patients were exposed to potentially toxic 
treatments and as there was nor is a comprehensive 
database, nobody could evaluate the outcome. The 
standard fractionation scheme for stage III NSCLC, 60 Gy 
in 2 Gy QD fractions was established in the 1980’s, but was 
already in use for many decades and has largely remained 
the same, while there have been countless patients who 
received other doses, fractions sizes and overall 
treatment times (OTT). Nobody knows what the results 
are. Accelerated radiotherapy was used since the 1920s, 
but before an influence on survival was demonstrated, we 
had to wait for the CHART trials in the 1990s and for level 
I evidence until 2012. At that time, concurrent chemo-
radiotherapy had become standard and we and others, 
without understanding the biology, used the same strategy 
of acceleration for the latter patients, unfortunately 
without benefit. Fortunately, improved techniques and 
integration of molecular imaging lead to less side effects 
than ever. 
 Stereotactic radiotherapy (SBRT) truly revolutionized our 
field, but at some moment, it was used at anatomical sides 
where it was predicted to be very toxic. Implementation 
without proper understanding of the underlying biology 
and prospective studies let to a high incidence of side 
effects and here again, the absence of a prospective 
database and the lack of formal testing precludes us to get 
more insights in the relation between toxicity and 
treatment and patients parameters.  
The technological evolution has overwhelmed the complex 
biology and its benefit is not assessed properly. 
Assumptions about gains are in general not supported by 
reproducible data with dose-escalation and adaptive 
radiotherapy as a good examples.  
 Immune treatment is now changing oncology profoundly 
and we should embrace this evolution. It gives us the 
platform to investigate the biology thoroughly, not only of 
photons, but also of protons and to revise fractionation 
and volumes. This will only work when we work with many 
other disciplines, perform pre-clinical and clinical trials 
and establish usable prospective databases. AI will be 
needed to learn from these networks with countless nodes 
and to implement the results. AI will also enable to take 
into account the (forgotten) knowledge of the past, to 
avoid making the same mistakes. 
Fractionation will however remain relevant. 
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Abstract text 
Human beings are able to survive within a  given 
environment as far as they are able to maintain an 
individual  balance (homeostasis), which is constantly 
challenged by intrinsic and extrinsic causes, also knowk as 
stress factors (1). Stress can be seen as a physiological 
response in the shape of a ‘general adaptation syndrome’ 
and can be subdivided into 3 different phases: a) alarm, 
b) resistance c) exhaust (1).  Individual can implement 
coping strategies in response to stress. They have 2 main 
goals: changing  the situation causing stress and 
controlling the emotional response to the stressful 
agent.  Certain coping strategies (emotional response) 
may  lead to exhaustion,  a final step in which the 
individual cannot accomplish to re-establish the inner 
balance.  This may lead to the so-called ‘Burn-out 
Syndome’ (BOS), which has been described by Maslach et 
al in the ‘90s (2). The terms forwards to a significance 
impling to burn something to exhaustion, until it is 
consumed (3). It is considered one of the montly impacting 
factor for physical and mental well-being within the 
working environment. It particularly affects healthcare 
professionals (4). The three classic presentation clusters 
are loss of enthusiasm for work (emotional exhaustion), 
reduced empathy and increased cynism 
(depersonalisation) and a decresed perception of the 
meaningfulness of someone’s work, finally leading to 
inefficacy (personal accomplishment) (2,4). Symptoms can 
be classified into  physical (insomnia, lack of energy, back 
pain, loss of appetite, ulcer, migraine, nausea) and 
psychological (cynism, irritability, denial of failures, loss 
of sense of humor, indifference, insecurity, disinterest, 
indecision, reduction of self-esteem and loss of memory) 
cluster. BOS is a stress-related syndrome and it is 
particularly frequent within Oncology professionals and 
staff (5). The incidence has been shown to be as high as 
50-70% (5-7). In team environments, such as in radiation 
oncology,  situations of increased job stress and burn-out 
can lead to impaired cognitive functioning, increasing the 
potenital for patient harm. BOS for hospital staff include 
illness, absenteeism, staff conflict, distrust of 
management, poor coping and substance abuse. Clinical 
consequences may include medical errors and adverse 
events, poor prescribing habits, low patients satisfaction 
and low adherence to physician recommendations (4). 
Different inherent factors may be related to BOS 
development. One of the most important is each 
individual’s coping style. Poor coping may lead to 
impairment in job performace and ineffective coping 
strategies may lead to a higher likelihood to develop BOS. 
In general, emotion-oriented coping styles are associated 
to higher levels of BOS (9). Personality traits may also 
predispose individuals to develop BOS. Alexithymia and 
empathy are personality traits. Alexithymia is a 
psychological construct broadly describing individuals with 
deficits in emotion processing and awareness (10). Those 
who score high on measure of alexithymia show difficulty 
distringushing emotions from bodily sensations, 
discrimitating between cognition and emotions and 
describing and communicationg emotions to others 
(11).  Empaty is the ability to share and understand 
another’s ‘state of mind’ or emotion. It is often 
characterized as the capacity to ‘put oneself into 
another’s shoes’. In the healthcare environment, effective 
emphatic communication enhances the therapeutic 
effectiveness of the clinician-patient relationship. The 
Young ESTRO Committee developed the PRO BONO study 
(PROject on Burn-Out in RadiatioN Oncology) to explore 
BOS in the field of radiation oncology and to investigate 
whether alexithymia and empathy  may potentially affect 
the likelihood for BOS development. The project is 
also  endorsed by the Young Radiation Oncology Group 
(yROG) of EORTC. The survey was aimed at all radiation 
oncology professionals and was completetly anonymous. 
This project will provide useful information. Being aware 
of potential risk factors may help in implementing 




protection startegies for radiation oncology professionals 
more prone to undergo BOS. Partecipants were asked to 
provide some general information and fill-in 3 different 
validated questionnaires (TAS-20, IRI, ProQoL) to 
investigate alexithymia trait , empathy and to quantify 
eventual BOS. The PRO-BONO initiative, is a valuable way 
to address an important issue, to analyze it and to define 
management strategies for individuals at risk of 
developing BOS. 
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Purpose or Objective 
Burn-out syndrome (BOS) is a stress-related syndrome, 
particularly frequent within Oncology professionals and 
staff. It may affect performance within the working 
environment and impact on individual physical and mental 
well-being. Personality traits may predispose to develop 
BOS. Alexithymia is a psychological construct describing 
deficits in emotion processing and awareness. Empathy is 
the ability to share and understand another’s ‘state of 
mind’ or emotion. The PROject on Burn-Out in RadiatioN 
Oncology (PRO BONO study) was developed to explore BOS 
in the field of radiation oncology and to investigate 
whether personality traits such as alexithymia and 
empathy  may potentially affect the likelihood to develop 
BOS. 
 
Material and Methods 
An anonymous survey was conducted online using the web-
based platform Survey Monkey (www.surveymonkey.com), 
addressed to ESTRO members, reached out via e-mail, 
social media or through the collaboration of National 
Societies. All professionals within ESTRO were involved 
(radiation oncologists, medical physicists, radiation 
therapists, radiobiologists). Partecipants were asked to 
provide specific individual and professional information 
and fill-in 3 different validated questionnaires to 
investigate alexithymia trait, empathy and to quantify 
BOS, namely the Toronto Alexithymia Scale (TAS-20), the 
Interpersonal Reactivity Index (IRI) and the Professional 
Quality of Life Scale (ProQoL). Answers were collected and 
results analysed by the Young ESTRO Committee.  
Results 
The survey is still open for response. So far, a total of 1958 
ESTRO members took part, from 94 different countries and 
5 continents. Male were 56%, female 44%. Most of 
respondents were radiation oncologists (53%), while 
radiation technologists were 26%, medical physicists 20% 
and radiobiologists 1%. As for educational level of 
respondents, most of them were MD (44%), MSc (18%) or 
BSc (13%), being in the field of radiation oncology for < 5 
year (28%) or between 11 and 20 years (27%). Up to 49% of 
them had on-call duties. Most of them (84%) pointed out 
that medical practice affected their private life. They felt 
valued by their patients in 88% of cases (not enough:12%) 
and by their supervisor in 72% (not enough:28%). Up to 32% 
had a 1-year leave from work. Preliminary results using 
Person correlation coefficient (PCC) showed a significant 
correlation (PCC=0.82) between a higher score (>61) on 
TAS-20  and a higher score (>57) on the burn-out subscale 
of the  ProQoL questionnaire. A higher score for Empathic 
Concern within the IRI questionnaire was also significantly 
correlated (PCC =0.79) to higher burn-out on ProQoL.    
Conclusion 
The PRO BONO study provided an overview on BOS, 
alexithymia and empathy in radiation oncology 
professionals worldwide. Personality traits such as 
alexithymia and empathy seem to be correlated to the 
likelihood to develop BOS. After the upcoming end of the 
study, detailed analysis on subset population and 
individual domains within administered questionnaires will 
better clarify the scenario.   
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Abstract text 
Concept of oligometastatic state, proposed by Hellman 
and Weichselbaum, implies that “there exists a subset of 
patients with limited volume metastases in whom 
treatment of oligometastatic sites impacts survival”. 
Randomized studies have demonstrated that surgical 
treatment of oligometastatic lesions can improve survival. 
Stereotactic body radiotherapy (SBRT) and Stereotactic 
Radiosurgery (SRS) has emerged as an attractive 
alternative or as an adjuvant to surgical resection. In this 
report we would like to review: the results of ablative 
radiotherapy for the intracranial and extracranial (lung, 
liver, spine) oligometastases ; recent attempts to identify 
the patients with limited number of metastases who 
mostly benefit from aggressive local treatment; data 
addressing fractionation regiments in regard to feasibility 
and safety of ablative radiotherapy for various 
localization, volume and size of metastases and short 
summary of my experience at the University Hospital 
Turin.Aiming to develop the concept of  stereotactic body 
radiotherapy and radiosurgery and introduce it in the 
clinical practice, we have set up collaborations and 
engaged discussion with Georgian colleagues. This process 
was enhanced by my visit to the department of Prof. 
Umberto Ricardi thanks to the mobility grant. Sharing the 
expertise of this department and  inspiring our self from 
the irradiation protocols developed by Prof. Umberto 
Ricardi and his group, now we are treating  this group of 
patients with oligometastatic disease and keeping 
institutional registry.The accumulating clinical data could 
be used in future to draw conclusions for safe and 
beneficial implementation of the existing guidelines. 
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